Drug Sales Trends for LAMISIL

Payment Methods and Pharmacy Types for LAMISIL (2007)

Revenues by Pharmacy Type

Pharmacy Type	Revenues
MAIL-ORDER	$9,943,942
INSIDE ANOTHER STORE	$108,119,421

Units Sold by Pharmacy Type

Pharmacy Type	Units
MAIL-ORDER	9,048
INSIDE ANOTHER STORE	314,347

Revenues by Payment Method

Payment Method	Revenues
MEDICARE	$43,203,248
PRIVATE INSURANCE	$273,323,683

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for LAMISIL

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
LAMISIL			2022
LAMISIL			2021
LAMISIL			2020
LAMISIL			2019
LAMISIL			2018

Lamisil Market Analysis, Sales Projections, Patent Expiration, and Generic Risk

Last updated: September 8, 2026

Lamisil is the brand name for terbinafine, an allylamine antifungal sold in oral tablets, topical creams, gels, sprays, and solutions. The brand generated peak annual sales of roughly $1 billion for Novartis before generic terbinafine and OTC competition eroded revenue. Current commercial value is concentrated in generic oral terbinafine and OTC topical products rather than the original prescription brand.

The Lamisil market is mature, price-sensitive, and largely exposed to generic substitution. A reasonable base-case estimate places global terbinafine product sales across branded, generic, and OTC channels at approximately $450 million to $650 million annually, with low single-digit growth through 2028. The branded Lamisil share is likely below 20% of global terbinafine value.

What is Lamisil and how does it make money?

Lamisil contains terbinafine hydrochloride. Oral terbinafine is used primarily for onychomycosis, while topical products treat tinea pedis, tinea corporis, and tinea cruris. The oral product is prescription-only in the United States. Several topical forms are sold over the counter in the U.S. and other major markets.

Product	Active ingredient	Main indication	Channel	Commercial position
Lamisil tablets	Terbinafine hydrochloride	Toenail and fingernail fungal infections	Prescription	Generic-dominated
Lamisil AT cream	Terbinafine hydrochloride	Athlete's foot and ringworm	OTC	Branded and private-label competition
Lamisil AT spray	Terbinafine hydrochloride	Athlete's foot	OTC	Convenience-led OTC segment
Lamisil topical solution or gel	Terbinafine hydrochloride	Superficial dermatophyte infections	OTC or prescription, depending on country	Fragmented
Generic terbinafine tablets	Terbinafine hydrochloride	Onychomycosis	Prescription	Primary volume product
Generic terbinafine topical products	Terbinafine hydrochloride	Superficial fungal infections	OTC or prescription	Low-cost competition

The oral tablet has a higher average treatment value than topical products because therapy may last 6 weeks for fingernail infections and 12 weeks or longer for toenail infections. Topical products have broader consumer reach but lower revenue per treatment course.

How large is the Lamisil and terbinafine market?

Public company filings no longer report Lamisil as a standalone material brand. Novartis reported Lamisil sales of approximately $1 billion during the brand's peak period, before loss of exclusivity and generic entry reduced the product's contribution.[1]

Current market value is best analyzed by product segment:

Segment	Estimated global annual value	2024-2028 outlook	Main growth driver
Generic oral terbinafine	$180 million-$280 million	1%-3% annual growth	Aging population and diagnosis of onychomycosis
Branded and generic topical terbinafine	$180 million-$270 million	2%-4% annual growth	OTC self-care and emerging-market access
Original Lamisil brand	$60 million-$120 million	Flat to declining	Brand recognition and pharmacy presence
Combination and private-label products	$30 million-$60 million	2%-5% annual growth	Retail and distributor expansion
Total terbinafine market	$450 million-$650 million	1%-4% annual growth	Volume growth offset by price erosion

These figures represent an analytical market model rather than reported consolidated sales. The market is highly fragmented, and many manufacturers report terbinafine revenue within broader dermatology or consumer-health categories.

What are the Lamisil sales projections through 2028?

The original Lamisil brand should remain a small but recognizable portion of the market. Generic substitution limits pricing power in oral terbinafine, while OTC shelf space and advertising support determine the performance of topical Lamisil.

Base-case projection

Year	Global terbinafine market	Original Lamisil brand	Generic and private-label share
2024	$450 million-$650 million	$60 million-$120 million	$390 million-$530 million
2025	$465 million-$670 million	$58 million-$115 million	$407 million-$555 million
2026	$480 million-$690 million	$56 million-$112 million	$424 million-$578 million
2027	$495 million-$715 million	$54 million-$109 million	$441 million-$606 million
2028	$510 million-$740 million	$52 million-$106 million	$458 million-$634 million

The model assumes:

• Oral generic volume grows by approximately 2% annually.
• Oral average selling prices decline by 2%-4% annually.
• OTC topical volume grows by 2%-4% annually.
• Branded Lamisil revenue declines by approximately 2%-5% annually.
• Emerging-market volume growth partly offsets mature-market price erosion.
• No major new terbinafine indication materially expands the market.

Bull case

A bull case would produce a 4%-6% annual market growth rate through 2028. The main drivers would be higher diagnosis rates for onychomycosis, increased use of oral therapy, stronger pharmacy distribution in Asia-Pacific and Latin America, and stable OTC pricing for branded spray and cream formats.

Bear case

A bear case would result in a market decline of 1%-3% annually. The principal risks are continued generic price compression, substitution by newer topical agents, limited physician use of oral therapy because of liver-safety monitoring, and weak consumer spending in OTC categories.

Which companies compete with Lamisil?

The competitive landscape differs sharply between oral and topical products.

Oral terbinafine competitors

Generic manufacturers compete primarily on price, supply reliability, regulatory compliance, and wholesaler access. The market includes regional generic companies and large multinational suppliers. Brand competition from itraconazole is clinically relevant, although itraconazole is not a direct formulation substitute in every case.

Competitor	Product	Competitive effect
Generic terbinafine manufacturers	Oral tablets	Direct substitution and price erosion
Itraconazole manufacturers	Oral capsules and solutions	Alternative systemic treatment
Fluconazole manufacturers	Oral products	Off-label or alternative antifungal use in some markets
Dermatology-focused companies	Newer topical agents	Compete for superficial and nail infections

Topical competitors

OTC topical competition includes clotrimazole, miconazole, butenafine, tolnaftate, and undecylenic acid products. Lamisil benefits from strong consumer recognition and a shorter advertised treatment course in some superficial fungal infections.

The main retail competitors are not limited to branded pharmaceutical companies. Retailer private labels, pharmacy generics, and e-commerce sellers can sell comparable terbinafine products at significant discounts.

When did Lamisil lose market exclusivity?

Lamisil's core oral and topical exclusivity expired years ago. FDA-approved generic terbinafine tablets are widely available, and topical terbinafine products are also sold by multiple manufacturers. The original product no longer has a meaningful composition-of-matter exclusivity barrier in the United States.

The key commercial events were:

Event	Approximate timing	Commercial effect
U.S. approval of oral Lamisil tablets	1996	Launch of prescription terbinafine for onychomycosis
Expansion of topical Lamisil products	1990s	Development of OTC and prescription dermatology franchise
Core patent expiry and generic entry	Mid-to-late 2000s	Rapid erosion of oral brand value
Broad generic availability	2010s	Oral terbinafine became a commodity product
Mature OTC competition	2010s-present	Brand value concentrated in consumer recognition and distribution

FDA labeling identifies oral Lamisil as terbinafine hydrochloride tablets for treatment of onychomycosis and includes liver-related warnings and monitoring information.[2]

What patents protect Lamisil?

The original Lamisil patent estate covered terbinafine and related pharmaceutical compositions, formulations, and uses. Those foundational rights have expired in the United States and other major markets.

Composition-of-matter patents

The composition patents covering terbinafine were the most commercially important rights. Their expiry enabled generic oral tablets and materially reduced the value of the prescription brand. No active U.S. composition patent should be expected to block ordinary generic terbinafine tablets.

Formulation patents

Formulation rights historically covered tablets, creams, gels, sprays, solutions, and delivery vehicles. These patents may have supported particular branded products, but they do not generally prevent competitors from selling terbinafine in a different formulation or under an approved generic pathway.

Method-of-use patents

Use claims have covered treatment of dermatophyte infections, including nail infections and superficial skin infections. These claims are old relative to current market entry and are unlikely to create a significant blocking position for standard terbinafine products.

Manufacturing and process rights

Manufacturing patents and proprietary process know-how may still affect cost, impurity control, and supply reliability. They do not create a broad market barrier because multiple manufacturers have established terbinafine production capabilities.

What is the Orange Book status of Lamisil?

Lamisil tablets were approved under FDA New Drug Application 020539. The FDA Orange Book historically listed patent and exclusivity information associated with the approved product. The practical market outcome is clear: generic terbinafine tablets are approved and commercially available, so the original Lamisil listing does not provide current product-level exclusivity against routine generic substitution.[3]

Orange Book considerations remain relevant for:

• Whether a particular generic can be substituted at the pharmacy.
• Patent certifications made by an abbreviated new drug application applicant.
• Any later-listed patents covering a specific formulation or use.
• Product-specific labeling differences.
• State-level substitution rules.

For ordinary terbinafine hydrochloride tablets, the principal commercial issue is price and distribution rather than Orange Book patent blocking.

Have companies challenged Lamisil through Paragraph IV filings?

Paragraph IV challenges were relevant during the original generic-entry period. A generic applicant could certify that a listed Lamisil patent was invalid, unenforceable, or would not be infringed. Those disputes helped determine the timing of generic entry in the mid-to-late 2000s.

Paragraph IV litigation is no longer the principal risk to the original brand because:

1. Core Lamisil patents have expired.
2. Generic terbinafine has broad market access.
3. Current competition is based on price, supply, and channel execution.
4. Any later patent would need to cover a commercially meaningful formulation or use rather than standard terbinafine itself.

Publicly material current Paragraph IV activity is not a central feature of the Lamisil market.

What patent litigation affects Lamisil?

Historical litigation centered on generic entry and the validity or scope of patents covering terbinafine products. The litigation risk today is limited relative to products with active composition patents or complex delivery systems.

Potential disputes could still arise over:

• A novel terbinafine formulation.
• A combination antifungal product.
• A narrow treatment method.
• Trade dress or trademark use involving the Lamisil name.
• Manufacturing processes or supply agreements.

These issues are unlikely to restore the original Lamisil brand's lost exclusivity.

What regulatory risks affect Lamisil sales?

The most important regulatory issue for oral terbinafine is hepatotoxicity. FDA labeling warns about liver failure, contraindications in chronic or active liver disease, and the need to evaluate patients before treatment.[2] These warnings can limit prescribing relative to topical products.

Key regulatory factors include:

Factor	Effect on market
Liver-safety labeling	Limits use in some patients
Prescription status of oral tablets	Restricts direct-to-consumer access
OTC status of many topical products	Supports self-treatment and retail volume
Generic ANDA pathway	Increases competition
Product quality and supply compliance	Determines generic availability
Country-specific switching rules	Affects brand retention

Biosimilar risk is not relevant. Terbinafine is a small-molecule chemical drug, not a biologic. Competition occurs through generic drug applications, OTC registrations, and national regulatory pathways rather than biosimilar approval.

How strong is the Lamisil patent estate?

The historical patent estate was commercially strong during the protected period because it covered a differentiated oral antifungal with high treatment value. Its current strength is weak as an exclusivity asset.

Patent category	Historical strength	Current strength
Terbinafine composition	High	Expired
Oral tablet formulation	Moderate to high	Largely expired or nonblocking
Topical formulation	Moderate	Limited, product-specific
Treatment methods	Moderate	Limited practical blocking value
Manufacturing process	Moderate	Supplier-level advantage only
Trademark and brand	High for recognition	Useful commercially, not a generic barrier

Lamisil's remaining defensibility is primarily commercial. Brand awareness, retail placement, formulation convenience, and physician familiarity matter more than patent protection.

What are the main generic launch scenarios?

Generic launch has already occurred in the core oral market. Future launches would mainly involve additional suppliers, dosage forms, OTC private labels, or emerging-market registrations.

Scenario	Probability	Market effect
Additional low-cost oral generic suppliers	High	More price erosion
Retail private-label topical terbinafine	High	Lower branded OTC share
Premium branded spray or gel formats	Moderate	Protects selected OTC revenue
New terbinafine combination product	Low to moderate	Creates niche growth
Reversal of generic substitution	Very low	No material effect expected

Generic competition will continue to pressure revenue per prescription. The main exception is a differentiated OTC format that improves convenience, adherence, or consumer recognition.

How does Lamisil compare with competing antifungals?

Attribute	Lamisil/terbinafine	Itraconazole	Clotrimazole	Newer topical agents
Main use	Nail and skin fungal infections	Systemic and nail infections	Skin and mucosal infections	Mainly nail infections
Oral form	Widely generic	Generic	Limited oral role	Usually topical
OTC presence	Strong topical presence	Limited	Strong	Limited
Generic pressure	Very high	High	Very high	Lower for patented products
Safety concern	Liver toxicity for oral use	Drug interactions and liver risk	Generally local tolerability	Product-specific
Pricing power	Low for oral; moderate for brand OTC	Low to moderate	Low	Higher where patented

Terbinafine retains a strong clinical and commercial position in dermatophyte infections, especially when physicians choose oral treatment for onychomycosis. Its economic position is weaker because the active ingredient is mature and widely available.

What is the revenue exposure for manufacturers?

Revenue exposure varies by company type:

• Original brand owner: low growth, declining or stable revenue.
• Generic manufacturer: volume opportunity with limited margins.
• OTC brand marketer: moderate opportunity tied to advertising and retail execution.
• API manufacturer: stable but price-sensitive demand.
• Specialty dermatology company: potential upside from differentiated nail-delivery technologies.

For a company dependent on Lamisil-branded sales, the key risk is continued substitution by generic and private-label products. For a generic manufacturer, the opportunity is reliable demand but limited pricing power. For an OTC operator, the strongest assets are brand recognition, retail distribution, and high-convenience formats.

Key Takeaways

• Lamisil is terbinafine, a mature small-molecule antifungal.
• Peak brand sales approached $1 billion before generic erosion.
• Current global terbinafine product value is estimated at $450 million-$650 million annually.
• The base-case market reaches approximately $510 million-$740 million by 2028.
• Original Lamisil revenue is estimated at $60 million-$120 million annually and is likely to decline gradually.
• Oral terbinafine is generic-dominated and exposed to price compression.
• OTC topical Lamisil retains value through brand recognition, retail distribution, and convenience formats.
• Core composition, formulation, and method-of-use exclusivities no longer create a meaningful U.S. market barrier.
• Biosimilar risk does not apply because terbinafine is a small-molecule drug.
• Future value depends more on consumer marketing, channel access, and formulation differentiation than on patent protection.

Frequently Asked Questions

Is Lamisil still a profitable drug?

Lamisil can remain profitable as an OTC brand, but the original prescription franchise has limited pricing power because generic terbinafine is widely available. Profitability depends on marketing efficiency, retail placement, and manufacturing cost.

Is terbinafine a generic for Lamisil?

Yes. Terbinafine hydrochloride is the active ingredient in Lamisil. Generic terbinafine tablets and topical products compete directly with the Lamisil brand.

Will Lamisil sales grow through 2030?

The original brand is more likely to remain flat or decline modestly. The broader terbinafine market may grow at a low single-digit rate through 2030, driven by population aging and demand for fungal infection treatment.

Does Lamisil have active U.S. patent protection?

The foundational U.S. patents covering terbinafine have expired. Product-specific patents, trademarks, or later formulation rights can differ, but they do not recreate broad exclusivity for standard terbinafine tablets.

Which drug competes most directly with oral Lamisil?

Generic terbinafine is the direct competitor. Itraconazole is the principal branded or generic systemic alternative, although clinical selection depends on infection type, patient risk, drug interactions, and physician judgment.

References

1. Novartis AG. (2007). Annual report 2006. https://www.novartis.com
2. U.S. Food and Drug Administration. (2023). Lamisil (terbinafine hydrochloride) tablets prescribing information. https://www.accessdata.fda.gov
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
5. U.S. National Library of Medicine. (2024). DailyMed: Terbinafine hydrochloride labeling. https://dailymed.nlm.nih.gov/dailymed/